

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tablets

Tier 2 – medium impact*

Date of issue: 14/09/2023

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tablets are out of stock until w/c 11th December 2023.
- Alternative continuous combined hormone replacement therapies (HRT) containing estradiol 1mg but a different progesterone component remain available and will be able to support increased demand.
- Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/2.5mg tablets remain available but cannot support uplift in demand.
- Where alternatives are not suitable, unlicensed supplies may be sourced, lead times vary

Actions Required

Prescribers should:

- not initiate patients on Indivina® 1mg/5mg tablets;
- consider prescribing an alternative continuous combined HRT product containing estradiol 1mg but a different progestogen component to Indivina®, ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose (see Supporting Information below);
- consider prescribing unlicensed products only where licensed alternatives are not appropriate. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see Supporting Information below).

Supporting Information

Clinical Information

The British Menopause Society (BMS) provides guidance from clinical experts on switching to alternative continuous combined HRT products. In this, BMS does acknowledge "The equivalence

Information produced by DHSC and disseminated by HSCB Pharmacy and Medicines Management Team. For most up-to-date information, visit <http://www.hscbusiness.hscni.net/services/3065.htm>

data included in this practical guide were based on a combination of pharmacokinetics, clinical trials and clinical experience. The dose equivalents included are subject to significant individual variations in absorption and metabolism."

When switching patients to an alternative HRT product, prescribers will consider symptom control, side effect profiles, breakthrough bleeds etc. The BMS also provides advice on managing side effects of oestrogen and progestogens where the options for progestogen side effects are: change the type of progestogen, reduce the dose if available, change the route of administration, alter the duration. [03-BMS-TfC-HRT-Practical-Prescribing-NOV2022-A.pdf \(thebms.org.uk\)](#)

Table 1: Alternative oral continuous combined hormone replacement therapies

Product	Active Ingredients
Femoston Conti® tablets	Estradiol 1mg/ Dydrogesterone 5mg
Kliovance tablets®	Estradiol 1mg/ Norethisterone 500mcg
Bijuve capsules®	Estradiol 1mg / Progesterone 100 mg

Guidance on ordering and prescribing unlicensed imports

The following specialist importers have confirmed they can source unlicensed unlicensed Indivina 1mg/2.5mg (please note there may be other companies that can also source supplies):

- Alium
- Target
- Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Please see the links below for further information:
 - [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency (MHRA)
 - [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society
 - [Prescribing unlicensed medicines](#), General Medical Council (GMC)

Links to further information:

- British Menopause Society HRT preparations and equivalent alternatives [15-BMS-TfC-HRT-preparations-and-equivalent-alternatives-NOV2022-A.pdf \(thebms.org.uk\)](#)
- HRT- Practical Prescribing [03-BMS-TfC-HRT-Practical-Prescribing-NOV2022-A.pdf \(thebms.org.uk\)](#)